SCHEMBL19981270

SCHEMBL19981270

NC(=O)C[C@H](NS(=O)(=O)N1CCOCC1)c1nc(-c2cnccn2)no1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BMP1 P13497 1/20 0.40
DPP4 P27487 1/20 0.38
DPP8 Q6V1X1 1/20 0.38
DPP9 Q86TI2 1/20 0.38
DPP7 Q9UHL4 1/20 0.38
TDP1 Q9NUW8 1/20 0.36
LRRK2 Q5S007 1/20 0.36
EPHX2 P34913 1/20 0.35
KCNH2 Q12809 1/20 0.35
ALDH1A1 P00352 2/20 0.35
ATM Q13315 1/20 0.35
PDF Q9HBH1 1/20 0.35
KDM4E B2RXH2 1/20 0.35
DYRK1A Q13627 4/20 0.35
GSK3B P49841 3/20 0.35
GAA P10253 1/20 0.34
POLB P06746 1/20 0.34
PKM P14618 1/20 0.34
MAPT P10636 1/20 0.34
HTT P42858 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19984850 0.83 HDAC6 (0.40) LRRK2DYRK1AGSK3BGAAPOLB
SCHEMBL19981145 0.83 BMP1 (0.49) BMP1DPP4DPP8DPP9DPP7
SCHEMBL19981328 0.83 BMP1 (0.36) BMP1DPP4DPP8DPP9DPP7
SCHEMBL19981308 0.77 BMP1 (0.39) BMP1DPP4DPP8DPP9DPP7
SCHEMBL19981246 0.76 BMP1 (0.40) BMP1DPP4DPP8DPP9DPP7
SCHEMBL19981329 0.75 VSIR (0.44) BMP1DPP4DPP8DPP9DPP7
SCHEMBL19981138 0.74 BMP1 (0.49) BMP1DPP4DPP8DPP9DPP7
SCHEMBL18078059 0.73 BMP1 (0.46) BMP1DPP4DPP8DPP9DPP7
SCHEMBL19981171 0.72 BMP1 (0.41) BMP1DPP4DPP8DPP9DPP7
SCHEMBL19981330 0.70 BMP1 (0.40) BMP1DPP4DPP8DPP9DPP7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2018051254-A1 CYCLIC SUBSTITUTED-1,2,4-OXADIAZOLE COMPOUNDS AS IMMUNOMODULATORS AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) 2018-03-22 WO disclosed